- Home
- KARD vs ABSI Comparison
KARD vs ABSI Comparison
Compare KARD & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KARD | ABSI |
|---|---|---|
| Founded | 2023 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KARD | ABSI |
|---|---|---|
| Price | $14.10 | $10.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $41.00 | $14.82 |
| AVG Volume (30 Days) | 577.7K | ★ 4.0M |
| Earning Date | 11-22-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | N/A | $39.03 |
| Revenue Next Year | $50.00 | $310.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.23 | $2.24 |
| 52 Week High | $27.00 | $12.54 |
Technical Indicators
Market Signals| Indicator | KARD | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 47.93 | 50.29 |
| Support Level | $13.75 | $8.15 |
| Resistance Level | $15.93 | $10.03 |
| Average True Range (ATR) | 0.99 | 0.95 |
| MACD | 0.32 | 0.16 |
| Stochastic Oscillator | 68.52 | 41.47 |
Price Performance
Historical ComparisonAbout KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.